A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Pimasertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Merck KGaA
- 07 Jun 2017 Biomarkers information updated
- 16 Feb 2017 Last checked against ClinicalTrials.gov record.
- 12 Feb 2017 Status changed from active, no longer recruiting to completed.